Literature DB >> 21174538

Epigenetic factors in cancer development: polycomb group proteins.

Andrea Piunti1, Diego Pasini.   

Abstract

The role of chromatin-modifying factors in cancer biology emerged exponentially in the last 10 years, and increased attention has been focused on Polycomb group (PcG) proteins and their enzymatic activities. PcG proteins are repressive chromatin modifiers required for proliferation and development. The frequent deregulation of PcG activities in human tumors has direct oncogenic effects and results, essential for cancer cell proliferation. Here we will review the recent findings regarding PcG proteins in prospective tumor development, focusing on the molecular mechanisms that deregulate PcG expression in different tumors, at the downstream pathways to PcG expression (that contribute to cancer development) and at the mechanisms that regulate PcG recruitment to specific targets. Finally, we will speculate on the benefit of PcG inhibition for cancer treatment, reviewing potential pharmacological strategies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21174538     DOI: 10.2217/fon.10.157

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  30 in total

Review 1.  Targeting the epigenome with bioactive food components for cancer prevention.

Authors:  Thomas Prates Ong; Fernando Salvador Moreno; Sharon Ann Ross
Journal:  J Nutrigenet Nutrigenomics       Date:  2012-02-22

Review 2.  ZRF1: a novel epigenetic regulator of stem cell identity and cancer.

Authors:  Luigi Aloia; Santiago Demajo; Luciano Di Croce
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

3.  Expression and clinicopathological significance of Mel-18 mRNA in colorectal cancer.

Authors:  Ji Tao; Yan-Long Liu; Gan Zhang; Yu-Yan Ma; Bin-Bin Cui; Yan-Mei Yang
Journal:  Tumour Biol       Date:  2014-06-27

4.  DZNep inhibits Hif-1α and Wnt signalling molecules to attenuate the proliferation and invasion of BGC-823 gastric cancer cells.

Authors:  Rui Huang; Xiu Jin; Yongying Gao; Hongmei Yuan; Fei Wang; Xiangmei Cao
Journal:  Oncol Lett       Date:  2019-08-22       Impact factor: 2.967

5.  The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers.

Authors:  Woo Kyun Bae; Kyung Hyun Yoo; Ji Shin Lee; Young Kim; Ik-Joo Chung; Min Ho Park; Jung Han Yoon; Priscilla A Furth; Lothar Hennighausen
Journal:  Mol Carcinog       Date:  2014-07-07       Impact factor: 4.784

Review 6.  Cancer control and prevention by nutrition and epigenetic approaches.

Authors:  Mukesh Verma
Journal:  Antioxid Redox Signal       Date:  2012-01-30       Impact factor: 8.401

7.  Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer.

Authors:  Yan-Long Liu; Xu Gao; Yang Jiang; Gan Zhang; Zi-Cheng Sun; Bin-Bin Cui; Yan-Mei Yang
Journal:  J Cancer Res Clin Oncol       Date:  2014-10-19       Impact factor: 4.553

8.  miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1.

Authors:  Shujing Liu; Michael T Tetzlaff; Rutao Cui; Xiaowei Xu
Journal:  Am J Pathol       Date:  2012-09-13       Impact factor: 4.307

9.  Inhibition enhancer of zeste homologue 2 promotes senescence and apoptosis induced by doxorubicin in p53 mutant gastric cancer cells.

Authors:  J Bai; M Ma; M Cai; F Xu; J Chen; G Wang; X Shuai; K Tao
Journal:  Cell Prolif       Date:  2014-04-16       Impact factor: 6.831

Review 10.  The roles of Polycomb repressive complexes in mammalian development and cancer.

Authors:  Andrea Piunti; Ali Shilatifard
Journal:  Nat Rev Mol Cell Biol       Date:  2021-03-15       Impact factor: 94.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.